The Impact of Osimertinib on Post-Surgery and Initial Advanced NSCLC
Osimertinib has been a game-changer in treating advanced non-small-cell lung cancer (NSCLC). But how does it fare when used as a first-line treatment for patients who have had surgery and later experienced a recurrence? That's a question that needs answering. While we know that post-surgery recurren